Genelux Co. (NASDAQ:GNLX - Get Free Report) major shareholder Aladar Szalay sold 48,683 shares of Genelux stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99. Following the sale, the insider now directly owns 1,322,862 shares in the company, valued at approximately $4,669,702.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Genelux Trading Up 6.8 %
NASDAQ GNLX opened at $3.86 on Friday. Genelux Co. has a 52 week low of $3.42 and a 52 week high of $40.98. The business's fifty day simple moving average is $6.25 and its 200-day simple moving average is $11.64.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. HC Wainwright lowered their target price on shares of Genelux from $35.00 to $32.00 and set a "buy" rating on the stock in a research note on Tuesday, April 2nd. Benchmark reiterated a "speculative buy" rating and set a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd.
Get Our Latest Stock Report on GNLX
Institutional Inflows and Outflows
Mysterious Gold Leverage Just Announced
From Stansberry Research | Ad
World's biggest multibillionaire investor group is buying THIS by the tons
Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.
Find out what it is and see how you can get in with just a few dollars.
Several institutional investors have recently modified their holdings of GNLX. Tower Research Capital LLC TRC purchased a new position in shares of Genelux during the 1st quarter worth $32,000. Citigroup Inc. purchased a new stake in Genelux in the 1st quarter valued at about $84,000. Charles Schwab Investment Management Inc. purchased a new stake in Genelux in the 1st quarter valued at about $421,000. BlackRock Inc. purchased a new stake in Genelux in the 1st quarter valued at about $402,000. Finally, Geode Capital Management LLC purchased a new stake in Genelux in the 1st quarter valued at about $1,046,000. Hedge funds and other institutional investors own 37.33% of the company's stock.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
